TLP Group’s DexCom DXCM Stock Holding History

TLP Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,616	Closed	-$38K	–	436
2018 Q2	$38K	Buy	+1,616	New	+$34.3K	0.06%	203
2018 Q1	–	Sell	-1,408	Closed	-$20K	–	444
2017 Q4	$20K	Buy	+1,408	New	+$18.3K	0.01%	266

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

TLP Group's DXCM Position: Q3 2018 in Review

TLP Group sold out of DexCom (DXCM) in Q3 2018, closing a stake of 1,616 shares — an estimated $38K sold.

TLP Group first reported a position in DXCM in Q4 2017 and held it in 2 quarters. The position peaked at $38K in Q2 2018. 363 funds tracked by Wall St. Rank hold DXCM as of Q3 2018.

TLP Group reported no remaining DexCom position as of Q3 2018 after selling out during the quarter.
TLP Group sold 1,616 DexCom shares in Q3 2018, an estimated $38K.
TLP Group first reported a position in DexCom in Q4 2017 and held it in 2 quarters.
TLP Group's DexCom position peaked at $38K in Q2 2018.
363 funds tracked by Wall St. Rank held DexCom as of Q3 2018.

Based on TLP Group's 13F filing for Q3 2018, filed 14 Nov 2018.